Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Defferrari · SciRah

Researcher profile · Semantic Scholar

C. Defferrari

Share profile

C. Defferrari — researcher profile on SciRah

h-index: 11
Works: 39
Citations: 471

Most-cited papers

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
F. Passiglia, F. Cappuzzo, O. Alabiso, A. Bettini +18 more
2018British Journal of Cancer77 citations Open access
Semantic Scholar
Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
F. Grossi, Marianna Aita, A. Follador, C. Defferrari +3 more
2007The Oncologist71 citations Open access
Semantic Scholar
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
F. Grossi, Marianna Aita, C. Defferrari, F. Rosetti +5 more
2009The Oncologist65 citations Open access
Semantic Scholar
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
Tania Buttiron Webber, N. Provinciali, M. Musso, Martina Ugolini +18 more
2021European Journal of Cancer39 citations Open access
Semantic Scholar
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Marianna Aita, G. Fasola, C. Defferrari, A. Brianti +5 more
2008Critical reviews in oncology/hematology36 citations
Semantic Scholar
Maintenance chemotherapy in non-small cell lung cancer.
M. Rinaldi, O. Belvedere, C. Cauchi, C. Defferrari +2 more
2006Annals of Oncology36 citations Open access
Semantic Scholar
Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma
Serena Patrone, I. Marić, M. Rutigliani, F. Lanza +15 more
2018Genes, Chromosomes and Cancer26 citations Open access
Semantic Scholar
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
M. Vitale, S. Scagliarini, L. Galli, S. Pignata +17 more
2018PLoS ONE25 citations Open access
Semantic Scholar
Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non–Muscle-Invasive Bladder Cancer
M. Puntoni, Marilena Petrera, S. Campora, E. Garrone +6 more
2016Cancer Prevention Research25 citations Open access
Semantic Scholar
An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab
M. D'Amico, M. Pagano, Ambra Pasa, M. Puntoni +12 more
2014Expert Opinion on Drug Safety13 citations
Semantic Scholar
Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
S. Campora, E. Campazzi, S. Zanardi, M. Puntoni +16 more
2016Translational Oncology12 citations Open access
Semantic Scholar
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
F. Grossi, E. Rijavec, M. G. Dal Bello, C. Defferrari +9 more
2012Cancer Chemotherapy and Pharmacology9 citations
Semantic Scholar
Patient‐ versus physician‐reported outcomes in a low‐dose tamoxifen trial in noninvasive breast cancer
Tania Buttiron Webber, D. Marra, M. Puntoni, Silvia Giuliano +10 more
2021The Breast Journal8 citations Open access
Semantic Scholar
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
O. Belvedere, A. Follador, C. Rossetto, V. Merlo +8 more
2011European Journal of Cancer5 citations
Semantic Scholar
Home Se-Cure: A Home Care Service for Cancer Patients during the COVID-19 Pandemic
Tania Buttiron Webber, Silvia Giuliano, C. Patrone, I. Briata +13 more
2021International Journal of Environmental Research and Public Health4 citations Open access
Semantic Scholar
A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
C. Defferrari, S. Campora, M. D'Amico, A. Piccardo +10 more
2012Journal of Ovarian Research4 citations Open access
Semantic Scholar
Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small cell lung cancer (NSCLC)
F. Grossi, A. Brianti, C. Defferrari, M. Loprevite +2 more
20073 citations
Semantic Scholar
Disease stabilization (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)
P. Pronzato, M. Loprevite, A. Brianti, C. Defferrari +2 more
20073 citations
Semantic Scholar
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. Role of the Research Nurse.
Tania Buttiron Webber, N. Provinciali, I. Briata, M. Boitano +7 more
2021Professioni infermieristiche2 citations
Semantic Scholar
The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
F. Passiglia, E. Capelletto, F. Grossi, P. Bidoli +15 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception
Martino Oliva, Monica Boitano, Alessio Carbone, I. Briata +13 more
2025BMC Cancer1 citations Open access
Semantic Scholar
Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations
F. Grossi, A. Brianti, C. Defferrari, P. Pronzato
20081 citations
Semantic Scholar
P3-090: Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)
F. Grossi, C. Defferrari, A. Brianti, G. Catania +3 more
20071 citations Open access
Semantic Scholar
Difference between skin toxicities in erlotinib (E) and gefitinib (G) in the treatment of advanced non-small cell lung cancer (NSCLC)
C. Defferrari, M. Loprevite, A. Brianti, G. Catania +2 more
20071 citations
Semantic Scholar
6625 POSTER Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
F. Grossi, A. Brianti, C. Defferrari, M. G. Dal Bello +3 more
20071 citations
Semantic Scholar
P3-089: Gefitinib (G) treatment outcome after progression on erlotinib (E) in patients with advanced non-small-cell lung cancer (NSCLC)
F. Grossi, C. Defferrari, A. Brianti, M. Loprevite +3 more
20071 citations Open access
Semantic Scholar
Second line chemotherapy with topotecan and gemcitabine in small cell lung cancer (SCLC) patients: An Alpe-Adria Thoracic Oncology Multidisciplinary group phase II study (ATOM 012).
O. Belvedere, C. Sacco, A. Ardizzoni, C. Rossetto +6 more
2006Journal of Clinical Oncology1 citations
Semantic Scholar
Effect of Distress, Anxiety, and Depressive Symptoms on SARS-CoV-2 mRNA BNT162b2 Vaccine Efficacy in Cancer Patients
G. Rondanina, Tania Buttiron Webber, O. D’Ecclesiis, Marco Musso +14 more
2024Cancers0 citations Open access
Semantic Scholar
Gender and Time-Related Differences in a Large Cohort of Heavy Smokers Applying for Treatment to a Tobacco Centre in Italy
C. Defferrari, C. Bárbara, M. Puntoni, Marilena Petrera +3 more
20180 citations
Semantic Scholar
Hormonal therapy for epithelial ovarian cancer: a systematic review and meta-analysis of phase II studies
L. Paleari, N. Provinciali, M. Puntoni, C. Defferrari +3 more
20160 citations Open access
Semantic Scholar
Endocrine therapy for ovarian cancer: A systematic review and meta-analysis of phase II studies.
L. Paleari, N. Provinciali, M. Puntoni, C. Defferrari +3 more
20160 citations
Semantic Scholar
A randomized trial of fenretinide in superficial bladder cancer: 20 year follow-up and prognostic significance of VEGF.
Marilena Petrera, M. Puntoni, S. Campora, C. Defferrari +6 more
20150 citations
Semantic Scholar
1329TiPA RANDOMIZED PHASE III MULTICENTER TRIAL OF CUSTOMIZED CHEMOTHERAPY VERSUS STANDARD OF CARE FOR 1ST LINE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): THE ELDERLY PATIENT INDIVIDUALIZED CHEMOTHERAPY (EPIC) TRIAL.
Tiziana Vavalà, S. Novello, F. Grossi, A. Misino +15 more
2014Annals of Oncology0 citations Open access
Semantic Scholar
Association of biomarkers with cardiac events during abiraterone acetate treatment in castration-resistant prostate cancer (CRPC).
S. Zanardi, S. Campora, M. Puntoni, M. Piccininno +8 more
20140 citations
Semantic Scholar
9089 Optimal duration of 1st- and 2nd-line chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC)
F. Grossi, O. Belvedere, C. Defferrari, C. Massoni +6 more
20090 citations
Semantic Scholar
125PD FINAL REPORT OF A RANDOMIZED PHASE II STUDY OF DOCETAXEL/OXALIPLATIN (DO) AND DOCETAXEL (D) IN PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS). AN ALPE-ADRIA THORACIC ONCOLOGY MULTIDISCIPLINARY GROUP STUDY (ATOM 019)
O. Belvedere, A. Follador, C. Rossetto, Angela Sibau +6 more
20090 citations
Semantic Scholar
Optimal duration of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC) in the first- and second-line settings.
F. Grossi, O. Belvedere, C. Defferrari, Annalisa Brianti +6 more
2009Journal of Clinical Oncology0 citations
Semantic Scholar
Final report of a randomized phase II study of docetaxel/oxaliplatin (DO) and docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patients (pts). A novel design, Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 019).
O. Belvedere, A. Follador, C. Rossetto, A. Sibau +6 more
2009Journal of Clinical Oncology0 citations
Semantic Scholar
6612 POSTER Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)
F. Grossi, C. Defferrari, A. Brianti, M. G. Dal Bello +3 more
20070 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Grossi×20
Invite
F. Grossi — researcher profile on SciRah
P. Pronzato×13
Invite
P. Pronzato — researcher profile on SciRah
A. Decensi×11
Invite
A. Decensi — researcher profile on SciRah
M. Puntoni×11
Invite
M. Puntoni — researcher profile on SciRah

×10

Invite

A. Follador — researcher profile on SciRah

N. Provinciali×10

Invite

N. Provinciali — researcher profile on SciRah

Invite

A. Brianti — researcher profile on SciRah

O. Belvedere×8

Invite

O. Belvedere — researcher profile on SciRah

Invite

A. Gozza — researcher profile on SciRah

Marianna Aita×7

Invite

Marianna Aita — researcher profile on SciRah

Invite

G. Fasola — researcher profile on SciRah

M. G. Dal Bello×7

Invite

M. G. Dal Bello — researcher profile on SciRah